PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)

Detalles Bibliográficos
Autores principales: Mato, A. R., Wierda, W. G., Pagel, J. M., Davids, M. S., Zinzani, P. L., Lu, Y., Liu, H., Shahda, S., Leow, C. C., Tam, C. S., Woyach, J. A., Eyre, T. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429380/
http://dx.doi.org/10.1097/01.HS9.0000850304.03677.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429380/
http://dx.doi.org/10.1097/01.HS9.0000850304.03677.28

Ejemplares similares